Increased circulating CD3⁺ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma

References

• Küppers R, Hansmann ML. The Hodgkin and reed/sternberg cell. Int J Biochem Cell Biol. 2005;37:511–517.
   PubMed Web of Science ®Google Scholar
• Pearce MS, Parker L, Windebank KP, et al. Cancer in adolescents and young adults aged 15-24 years: A report from the North of England young person’s malignant disease registry, UK. Pediatr Blood Cancer. 2005;45:687–693.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist. 2006;11:590–601.
   PubMed Web of Science ®Google Scholar
• Petrova GD, Melkova KN, Chernyavskaya TZ, et al. Autologous stem cell transplantation in primary refractory Hodgkin’s lymphoma: supposed Zugzwang or Zwischenzug? Klin Onkogematol Russian. 2015;8:321–330.
   Google Scholar
• Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–168.
   PubMed Web of Science ®Google Scholar
• Mendler JH, Friedberg JW. Salvage therapy in Hodgkin's lymphoma. Oncologist. 2009;14:425–432.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Ascani S, Leoncini L, et al. Hodgkin’s lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002;55:162–176.
   PubMed Web of Science ®Google Scholar
• Montanari F, Diefenbach CS. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy. Clin Adv Hematol Oncol. 2015;13:518–524.
   PubMed Web of Science ®Google Scholar
• Wein F, Küppers R. The role of T cells in the microenvironment of Hodgkin lymphoma. J Leukoc Biol. 2016;99:45–50.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2013;31:256–262.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200.
   PubMed Web of Science ®Google Scholar
• Koreishi AF, Saenz AJ, Persky DO, et al. The Role of Cytotoxic and Regulatory T cells in Relapsed/Refractory Hodgkin Lymphoma. Appl Immunohistochem Mol Morphol. 2010;18:206–211.
   PubMedGoogle Scholar
• Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31–39.
   PubMed Web of Science ®Google Scholar
• Álvaro-naranjo T, Lejeune M, Salvadó-Usach MT, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk. Lymphoma. 2005;46:1581–1591.
   PubMed Web of Science ®Google Scholar
• Alonso-Álvarez S, Vidriales MB, Caballero MD, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017;58:1144–1152.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s Lymphoma. Bone Marrow Transplant. 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:116–124.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin’s disease. Br J Haematol. 2002;117:629–633.
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;34:43–49.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Herr AL, Deb Edwardes MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology. 2006;11:165–170.
   PubMed Web of Science ®Google Scholar
• Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–657.
   PubMed Web of Science ®Google Scholar
• Koehne G, Zeller W, Stockschlaeder M, et al. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:149–156.
   PubMed Web of Science ®Google Scholar
• Steingrimsdottir H, Gruber A, Björkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85:832–838.
   PubMed Web of Science ®Google Scholar
• Schlenke P, Sheikhzadeh S, Weber K, et al. Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:251–257.
   PubMed Web of Science ®Google Scholar
• Rueff J, Medinger M, Heim D, et al. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014;20:896–899.
   PubMed Web of Science ®Google Scholar
• van den Brink MRM, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematol Am Soc Hematol Educ Progr. 2015;2015:215–219.
   PubMedGoogle Scholar
• Atanackovic D, Cao Y, Luetkens T, et al. CD4 + CD25 + FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008;93:423–430.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479–1493.
   PubMed Web of Science ®Google Scholar
• Ganeshan P, Gupta R, Hakim M, et al. Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma. Int J Hematol. 2011;94:578–579.
   PubMed Web of Science ®Google Scholar
• Batorov EV, Tikhonova MA, Pronkina NV, et al. Increased circulating CD4 +FOXP3 + T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients. Oncotarget. 2018;9:27305–27317.
   PubMedGoogle Scholar
• Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematol Am Soc Hematol Educ Program. 2008;2008:326–333.
   Google Scholar
• Alinari L, Blum KA. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood. 2016;127:287–295.
   PubMed Web of Science ®Google Scholar
• Porrata L, Inwards DJ, Ansell SM, et al. Sustained natural killer cell recovery post-autologous peripheral blood hematopoietic stem cell transplantation predicts survival in non-Hodgkin’s lymphoma. Blood. 2016;128:4641.
   Google Scholar
• Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122:2856–2863.
   PubMed Web of Science ®Google Scholar
• Di Gaetano R, Gasparetto V, Padoan A, et al. Flow cytometry CD4(+)CD26(-)CD38(+) lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes. Ann Hematol. 2014;93:1319–1326.
   PubMed Web of Science ®Google Scholar
• Gunduz E, Sermet S, Musmul A. Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients. Cytometry. 2016;90:449–454.
   PubMedGoogle Scholar
• Chang C, Wu SY, Kang YW, et al. High levels of regulatory t cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma. Am J Clin Pathol. 2015;144:935–944.
   PubMed Web of Science ®Google Scholar
• Głowala-Kosińska M, Chwieduk A, Nieckula J, et al. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol. 2013;91:122–128.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. Rieux-Laucat F, editor. PLoS One. 2012;7:e47077.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106:546–552.
   PubMed Web of Science ®Google Scholar